Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,172.00",
    "chg": -3,
    "chgp": "-0.26%",
    "dir": -1,
    "prev_price": "1,175.00",
    "mcapval": "97,624.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Aug 07, 03:30 PM",
    "curr_time": "17:55 PM",
    "last_traded_at": "Aug 07, 03:30 PM IST",
    "bse_nse_vol": "11.38 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 07, 2026",
    "traded_date_str": "2026 08 07",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories Gains 2.13%: 4 Key Technical Shifts Shape Weekly Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-gains-213-4-key-technical-shifts-shape-weekly-trend-4143433",
        "imagepath": "",
        "date": "2026-08-08 16:00:07",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>3 Aug:</strong> Stock opens strong at ₹1,169.90 (+1.94%)</p>\n                    <p><strong>4 Aug:</strong> Technical momentum shifts from sideways to mildly bearish</p>\n                    <p><strong>6 Aug:</strong> Death Cross formation signals bearish trend</p>\n                    <p><strong>7 Aug:</strong> Bearish technical shift confirmed amid mixed momentum signals</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,147.60</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,172.0..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Faces Bearish Technical Shift Amid Mixed Momentum Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-bearish-technical-shift-amid-mixed-momentum-signals-4140988",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/DrReddysLaborat_technicaldot_4140988.png",
        "date": "2026-08-07 08:03:47",
        "description": "Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a marginal day change of 0.09%, the stock’s technical parameters, including MACD, RSI, and moving averages, suggest increasing downside pressure amid a challenging market backdrop for the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Forms Death Cross Signalling Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-forms-death-cross-signalling-bearish-trend-4140316",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/DrReddysLaborat_dealthcross_4140316.png",
        "date": "2026-08-06 18:00:30",
        "description": "Dr Reddys Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting a deterioration in the stock’s momentum and raising concerns about its medium to long-term outlook."
      },
      {
        "title": "P/E at 30.41 vs Industry's 36.91: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-mixed-market-performance-and-institutional-shifts-4139457",
        "imagepath": "",
        "date": "2026-08-06 09:21:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p>The stock’s P/E ratio of 30.41 represents a discount of approximately 17.6% relative to the sector average of 36.91. This valuation gap suggests that the market is pricing in either subdued growth expectations or heightened risk compared to peers within the Pharmaceuticals & Biotechnology sector. Such a premium or discount often reflects investor sentiment on earnings sustainability and sector cyclicality. In this case, the discount may indicate caution despite the company’s established market presence and mid-cap status with a market capitalisation of ₹97,991 crores.</p>\n                <p>This valuation context raises the question: <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-sell-4137955",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/DrReddysLaborat_mojoScore_4137955.png",
        "date": "2026-08-05 10:10:03",
        "description": "Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 August 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Bearish Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-amid-bearish-signals-4137022",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/DrReddysLaborat_technicaldot_4137022.png",
        "date": "2026-08-05 08:04:28",
        "description": "Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a complex market sentiment for the mid-cap pharmaceutical giant."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-amid-mixed-market-signals-4134891",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/DrReddysLaborat_technicaldot_4134891.png",
        "date": "2026-08-04 08:06:45",
        "description": "Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest daily gain of 1.94%, the pharmaceutical giant’s broader technical signals present a mixed picture, with key oscillators and moving averages offering contrasting insights into its near-term trajectory."
      },
      {
        "title": "P/E at 29.79 vs Industry's 37.19: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-mixed-performance-and-institutional-shifts-4133116",
        "imagepath": "",
        "date": "2026-08-03 09:20:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 29.79, which is approximately 20% below the Pharmaceuticals & Biotechnology industry average of 37.19. This discount suggests the market is pricing in either slower growth prospects or elevated risks relative to peers. The mid-cap stock’s market capitalisation stands at ₹97,081.14 crores, positioning it well within the sector but not among the largest players. The valuation gap raises the question of whether the discount reflects a value opportunity or a justified caution — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" cla..."
      },
      {
        "title": "P/E at 29.64 vs Industry's 37.11: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-mixed-market-performance-and-nifty-50-membership-significance-4129736",
        "imagepath": "",
        "date": "2026-07-31 09:21:17",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premium</strong></p>\n                <p>The stock’s P/E ratio of 29.64 stands well below the industry average of 37.11, indicating that <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> is trading at a roughly 20% discount relative to its sector peers. This valuation gap may reflect investor concerns about recent earnings growth or broader market sentiment towards the company’s prospects. The sector’s elevated P/E suggests that investors are willing to pay a premium for growth or stability in other pharmaceutical companies, whereas <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> is viewed mor..."
      }
    ],
    "total": 641,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "01-Aug-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015- Press Release",
      "source": "BSE"
    },
    {
      "caption": "Announcement Under Regulation 30 Of SEBI (LODR) Regulation 2015",
      "datetime": "29-Jul-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Clarification-Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "29-Jul-2026",
      "details": "Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Reddys Laboratories Gains 2.13%: 4 Key Technical Shifts Shape Weekly Trend

2026-08-08 16:00:07

Key Events This Week

3 Aug: Stock opens strong at ₹1,169.90 (+1.94%)

4 Aug: Technical momentum shifts from sideways to mildly bearish

6 Aug: Death Cross formation signals bearish trend

7 Aug: Bearish technical shift confirmed amid mixed momentum signals

Week Open

Rs.1,147.60

Week Close

Rs.1,172.0...

Read full news article

Dr Reddys Laboratories Ltd Faces Bearish Technical Shift Amid Mixed Momentum Signals

2026-08-07 08:03:47

Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. Despite a marginal day change of 0.09%, the stock’s technical parameters, including MACD, RSI, and moving averages, suggest increasing downside pressure amid a challenging market backdrop for the Pharmaceuticals & Biotechnology sector.

Read full news article

Dr Reddys Laboratories Ltd Forms Death Cross Signalling Bearish Trend

2026-08-06 18:00:30

Dr Reddys Laboratories Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting a deterioration in the stock’s momentum and raising concerns about its medium to long-term outlook.

Read full news article

P/E at 30.41 vs Industry's 36.91: What the Data Shows for Dr Reddys Laboratories Ltd

2026-08-06 09:21:06

Valuation Picture: Discount to Industry P/E

The stock’s P/E ratio of 30.41 represents a discount of approximately 17.6% relative to the sector average of 36.91. This valuation gap suggests that the market is pricing in either subdued growth expectations or heightened risk compared to peers within the Pharmaceuticals & Biotechnology sector. Such a premium or discount often reflects investor sentiment on earnings sustainability and sector cyclicality. In this case, the discount may indicate caution despite the company’s established market presence and mid-cap status with a market capitalisation of ₹97,991 crores.

This valuation context raises the question: Read full news article

Dr Reddys Laboratories Ltd is Rated Sell

2026-08-05 10:10:03

Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 August 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Bearish Signals

2026-08-05 08:04:28

Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a complex market sentiment for the mid-cap pharmaceutical giant.

Read full news article

Dr Reddys Laboratories Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-08-04 08:06:45

Dr Reddys Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest daily gain of 1.94%, the pharmaceutical giant’s broader technical signals present a mixed picture, with key oscillators and moving averages offering contrasting insights into its near-term trajectory.

Read full news article

P/E at 29.79 vs Industry's 37.19: What the Data Shows for Dr Reddys Laboratories Ltd

2026-08-03 09:20:47

Valuation Picture: Discount to Industry P/E

Dr Reddys Laboratories Ltd trades at a P/E multiple of 29.79, which is approximately 20% below the Pharmaceuticals & Biotechnology industry average of 37.19. This discount suggests the market is pricing in either slower growth prospects or elevated risks relative to peers. The mid-cap stock’s market capitalisation stands at ₹97,081.14 crores, positioning it well within the sector but not among the largest players. The valuation gap raises the question of whether the discount reflects a value opportunity or a justified caution — Read full news article

P/E at 29.64 vs Industry's 37.11: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-31 09:21:17

Valuation Picture: Discount Amidst Sector Premium

The stock’s P/E ratio of 29.64 stands well below the industry average of 37.11, indicating that Dr Reddys Laboratories Ltd is trading at a roughly 20% discount relative to its sector peers. This valuation gap may reflect investor concerns about recent earnings growth or broader market sentiment towards the company’s prospects. The sector’s elevated P/E suggests that investors are willing to pay a premium for growth or stability in other pharmaceutical companies, whereas Dr Reddys Laboratories Ltd is viewed mor...

Read full news article

View All News